Edition:
United Kingdom

Neovasc Inc (NVCN.OQ)

NVCN.OQ on NASDAQ Stock Exchange Capital Market

0.57USD
8:59pm GMT
Change (% chg)

$-0.00 (-0.58%)
Prev Close
$0.57
Open
$0.59
Day's High
$0.59
Day's Low
$0.57
Volume
87,145
Avg. Vol
83,271
52-wk High
$2.14
52-wk Low
$0.56

Chart for

About

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment... (more)

Overall

Beta: 2.82
Market Cap(Mil.): $154.31
Shares Outstanding(Mil.): 78.91
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 168.71 16.44
EPS (TTM): -- -- --
ROI: -- 9.50 10.62
ROE: -- 14.87 14.20

BRIEF-Capital World Investors Reports A 13.8 Percent Passive Stake In Neovasc Inc

* CAPITAL WORLD INVESTORS REPORTS A 13.8 PERCENT PASSIVE STAKE IN NEOVASC INC AS OF NOVEMBER 30, 2017 - SEC FILING Source text : [http://bit.ly/2kZxgLY] Further company coverage:

11 Dec 2017

BRIEF-Neovasc announces qtrly loss per share $0.06

* Neovasc Inc - ‍Revenues decreased 55% to $1.4 million for three months ended September 30, 2017, compared to revenues of $3.0 million ​

14 Nov 2017

BRIEF-Neovasc announces 65 million dollars offering of common shares and warrants

* NEOVASC ANNOUNCES US$65 MILLION UNDERWRITTEN OFFERING OF UNITS CONSISTING OF COMMON SHARES AND WARRANTS TO PURCHASE COMMON SHARES AND CONCURRENT PRIVATE PLACEMENT OF NOTES AND WARRANTS

10 Nov 2017

BRIEF-Neovasc receives FDA approval to initiate pivotal reducer trial

* Neovasc receives FDA approval to initiate pivotal reducer trial

06 Nov 2017

BRIEF-Neovasc provides litigation update

* Says Court Of Appeals affirmed judgment of U.S. District Court for District of Massachusetts in case of Cardiaq Valve Tech versus co

03 Nov 2017

BRIEF-Neovasc provides Tiara clinical update

* Neovasc Inc - ‍all cause, 30-day mortality in 33 patients who have reached 30 days post implant with Tiara is 12.1% (4/33) in Tiara trial​ Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Neovasc reports Q2 loss per share $0.07

* Qtrly loss per share $0.07 Source text for Eikon: Further company coverage:

10 Aug 2017

Earnings vs. Estimates